

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

757



Fig. Angiography computed tomography three-dimensional reconstruction of three cases of infrapopliteal arterial thrombosis.

Of the four cases, two underwent surgery. One patient had undergone open bilateral popliteal direct thrombectomy of all distal vessels and one had undergone open femoralpopliteal and radial-ulnar thrombectomy. Both patients recovered immediate patency of all declotted arteries and experienced improved clinical symptoms, despite the finding of segmental distal asymptomatic rethrombosis at 24 hours after surgery (plantar arch or one of the distal infrapopliteal vessels). The other two patients did not undergo surgery because of their extremely poor respiratory condition and relatively well-tolerated ischemia; these patients have continued to receive follow-up.

The vascular community should be aware of this new thrombotic complication in critically ill patients with COVID-19. It can be due to the hypercoagulable secondary status, and surgery is a valuable treatment option for complicated cases, despite the risk of rethrombosis.

Gaspar Mestres, MD, PhD Roger Puigmacià, MD Carla Blanco, MD Xavier Yugueros, MD, PhD Montserrat Esturrica. MD Vincent Riambau, MD, PhD Department of Vascular Surgery

Cardiovascular Institute Hospital Clinic Barcelona University of Barcelona Barcelona, Spain

REFERENCES

- 1. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19 [published online ahead of print April 13, 2020]. Am J Hematol doi: 10.1002/ajh.25829.
- 2. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET) [published online ahead of print April 8, 2020]. Blood Transfus doi: 10.2450/2020.0083-20.
- 3. Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series [published online ahead of print April 8, 2020]. J Thromb Haemost doi: 10.1111/jth.14828.
- 4. Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz A, Kakavand H, et al. Cardiovascular considerations in treating patients with coronavirus (COVID-19) [published online ahead of print April 2, 2020]. J Cardiovasc Pharmacol doi: 10.1097/ FJC.000000000000836.

https://doi.org/10.1016/j.jvs.2020.04.477

Intra-arterial thrombosis associated with COVID-19



Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global pandemic. The development of an acquired thrombophilia with activation of the coagulation cascade in response to the inflammatory process has been described. SARS-CoV-2 appears to have an affinity for angiotensin-converting enzyme 2 receptors that seem to be downregulated, which may drive the proinflammatory/prothrombotic consequences.2

As this is a novel illness, there has been limited opportunity to understand and to investigate the effect of SARS-CoV-2. In severe disease, there appears to be elevation of D-dimer levels. Prolongation of prothrombin time and activated partial thromboplastin time seems to be associated with an increased risk of acute respiratory distress syndrome and death.³ The development of disseminated intravascular coagulation appears to be common in nonsurvivors.4

There appears to be an increased risk of pulmonary thromboembolic events in ventilated patients with SARS-CoV-2, despite the administration of lowmolecular-weight heparin prophylaxis. In a small series of minimally invasive autopsies, a significant proportion of patients were found to have small fibrinous thrombi in pulmonary arterioles. Similar data have been described across Europe with revision of low-molecular-weight heparin prophylaxis dosing. As well as the described pulmonary thrombotic complications, a series of early circuit occlusions has been encountered in patients on hemofiltration as a consequence of multiple organ dysfunction syndrome from SARS-CoV-2.

Recently, a small number of patients have presented with systemic intra-arterial thrombosis and a diagnosis of SARS-CoV-2. There is some evidence to suggest that this may occur, with a small series reporting ischemic strokes in patients in intensive care units. In our experience, patients presenting with limb-threatening ischemia and SARS-CoV-2 have had no other clear reason for development of intra-arterial thrombosis. Management has been dictated primarily by the severity of the organ dysfunction. A conservative approach with the prescription of therapeutic low-molecular-weight-heparin with subsequent conversion to a direct-acting oral anticoagulant has been an effective strategy.

Vascular surgeons have to recognize the potential for limb- and life-threatening arterial occlusion events in patients with SARS-CoV-2. Further research is required to try to elucidate the mechanisms by which this disease process activates the coagulation cascade.

Kirsten Victoria Hamilton, MBChB, MRCS Ed Keith Kelso Hussey, MBChB, FRCS Ed, MD

Queen Elizabeth University Hospital Glasgow, Scotland

REFERENCES

- Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, Ferraz da Silva LF, Pierre de Oliveira E, Nascimento Saldiva PH, et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost 2020;18: 1517-9.
- Liu PP, Blet A, Smyth D, Li H. The science underlying COVID-19: implications for the cardiovascular system. Circulation 2020:142:68-78.
- Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020;95:834-47.
- Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844-7.
- Klok F, Kruip M, Meer NV, Arbous M, Gommers D, Kant K, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145-7.

https://doi.org/10.1016/j.jvs.2020.05.019

An increased severity of peripheral arterial disease in the COVID-19 era



The recent coronavirus 2019 (COVID-19) pandemic has significantly increased the pressure on our healthcare system around the world. The health emergency has changed the organization of health institutions and focused attention on pandemic management. This has led to important changes in the treatment of patients without COVID-19 and has resulted in the most difficult access to care with delays in diagnosis and treatment. Vascular diseases, including peripheral arterial disease,

will require rapid treatment in most cases. The severity of peripheral arterial disease is assessed using a functional classification system (Fontaine or Rutherford). The most severe grades of classifications include critical limb ischemia (CLI). CLI is defined by limb pain at rest, nonhealing wounds or ulcers, and/or gangrene in one or both legs.¹ CLI requires rapid revascularization to avoid tissue loss and amputation. The introduction of the lockdown in Italy from March 9, 2020, led to the closure of outpatient activities and prevented early observation of patients with CLI. Furthermore, the fear of contagion led to an underestimation of the symptoms and delayed access to treatment through the emergency room. Thus, patients with severe CLI with significant septic ulcers and gangrene arrived at our vascular surgery department. For most of these patients, it was not possible to save the limbs, and, therefore, they underwent amputation surgery. We observed that the number of amputations performed in our department from March 9 to April 20, 2020, was significantly greater than the number performed in the same period in 2019. Specifically, we performed 9 amputations during this period compared with 5 amputations performed in 2019 in the same period; an increase of almost 50%. We believe that the COVID-19 pandemic has led to the poor treatment of patients with other pathologic entities; thus, it is necessary to adopt more suitable measures to avoid other serious consequences on the health of citizens. Consequently, it is necessary to identify paths that will allow these patients to have rapid access to treatment with marked improvements in outcome.

Giuseppe Sena, MD Giuseppe Gallelli, MD

Department of Vascular Surgery "Pugliese-Ciaccio" Hospital Catanzaro, Italy

REFERENCE

 Gerhard-Herman MD, Gornik HL, Barratt C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/ American Heart Association Task Force on clinical practice guidelines. Circulation 2017;135:726-79.

https://doi.org/10.1016/j.jvs.2020.04.489

Cardiovascular examination should also include peripheral arterial evaluation for COVID-19 patients



The global impact of coronavirus disease (COVID-19) on vascular surgical services has been initially addressed by Ng et al. This change in how vascular surgery